Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

February 23, 2023

Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.

February 20, 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

February 20, 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

February 16, 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

February 16, 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

February 14, 2023

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

February 13, 2023

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

February 09, 2023

Experts in metastatic colorectal cancer management highlight the role of molecular testing and testing modalities available in the academic and community settings.

October 21, 2022

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

October 21, 2022

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

October 17, 2022

Wade T. Iams, MD, discusses the potential for providing small cell lung cancer subtyping in clinical practice.

October 11, 2022

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

August 16, 2022

Kathryn E. Beckermann, MD, PhD, discusses the future of treatment in renal cell carcinoma.

August 08, 2022

The addition of fruquintinib to best supportive care improved overall survival compared with BSC alone in patients with metastatic colorectal cancer who progressed on standard chemotherapy and relevant biologic agents, and who had progressed on or were intolerant to trifluridine/tipiracil and/or regorafenib.

August 03, 2022

Vanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.

July 14, 2022

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.

July 11, 2022

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

July 07, 2022

Ben Ho Park, MD, PhD, summarizes exciting data regarding circulating tumor DNA testing, including its ability to determine the benefits of adjuvant chemotherapy, its successful preliminary use in detecting cancer prior to recurrence, and how it may help guide future therapies.

June 04, 2022

Guided approaches leveraging circulating tumor DNA status can reduce the number of patients who receive adjuvant chemotherapy without the risk of lowering recurrence-free survival rates for some patients with stage II colon cancer.

March 01, 2022

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.